AVITA Medical's EPS (Basic) for the
three
months ended in Mar. 2024 was €-0.67.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.63.
During the past 3 years, the average EPS without NRIGrowth Rate was 12.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 4.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 1.60% per year.
During the past 13 years, AVITA Medical's highest 3-Year average EPS without NRI Growth Rate was 72.40% per year. The lowest was -78.80% per year. And the median was 12.00% per year.
AVITA Medical Earnings per Share (Diluted) Historical Data
The historical data trend for AVITA Medical's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVITA Medical's Earnings per Share (Diluted)
For the Medical Devices subindustry, AVITA Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's PE Ratio distribution charts can be found below:
* The bar in red indicates where AVITA Medical's PE Ratio falls into.
AVITA Medical Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
AVITA Medical's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
AVITA Medical (FRA:51KA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AVITA Medical Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of AVITA Medical's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:51KA has been successfully added to your 